<!DOCTYPE html>
<html>
    <head>
        <meta charset="utf-8" />
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=1.0, maximum-scale=1.0, minimum-scale=1.0, user-scalable=no" />
        <title>References</title>

        <link href="../jquery-mobile/jquery.mobile.theme-1.2.0.min.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.swatch.f.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.swatch.l.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/custom_arrow.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.structure-1.2.0.min.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/full.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/recreated_tables.css" rel="stylesheet" type="text/css"/>
        <script src="../jquery-mobile/jquery-1.8.2.min.js" type="text/javascript"></script>
        <script src="../jquery-customization.js" type="text/javascript"></script>
        <script src="../jquery-mobile/jquery.mobile-1.2.0.min.js" type="text/javascript"></script>
        <script src="../cordova-2.2.0.js" type="text/javascript" charset="utf-8"></script>
        <script src="../assets/js/metrics.js" type="text/javascript" charset="utf-8"></script>

    </head>
    <body>

        <!-- Start of page -->
        <div data-role="page" id="heading_page_4" data-theme="d">
            <div data-role="header" data-id="references-header" data-theme="l" data-position="fixed">
                <a href="lv-0.html" data-role="button" data-iconshadow="false" data-corners="false" data-theme="reset" data-transition="fade" class="back_button" role="button" aria-label="back"></a>
                <h1>References</h1>
	            <a href="../menu.html"  rel="external" data-role="button" data-theme="reset" data-transition="fade" data-iconshadow="false" data-corners="false" class="menu_button ui-btn-right" role="button" aria-label="main menu"></a>
            </div>  <!-- end of header div -->

            <div data-role="content">
            <div id=references_breadcrumbs>
            
                    <a href="lv-0.html" >References</a><span class="carrot"> > </span>References 151-200
            </div>   <!-- end of references listview breadcrumbs -->
            </br><h1 id="sigil_toc_id_3">
 References 151-200
</h1>
<p>
 151. Engelberg R, Carrell D, Krantz E, et al. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis 2003;30:174&ndash;7.
</p>
<p>
 152. Scoular A. Using the evidence base on genital herpes: optimising the use of diagnostic tests and information provision. Sex Transm Infect 2002;78:160&ndash;5.
</p>
<p>
 153. Scoular A, Gillespie G, Carman WF. Polymerase chain reaction for diagnosis of genital herpes in a genitourinary medicine clinic. Sex Transm Infect 2002;78:21&ndash;5.
</p>
<p>
 154. Wald A, Huang ML, Carrell D, et al. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces:&nbsp;comparison with HSV isolation in cell culture. J Infect Dis 2003;188:1345&ndash;51.
</p>
<p>
 155. Ashley R, Cent A, Maggs V, et al. Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med 1991;115:520&ndash;6.
</p>
<p>
 156. Song B, Dwyer DE, Mindel A. HSV type specific serology in sexual health clinics: use, benefits, and who gets tested. Sex Transm Infect 2004;80:113&ndash;7.
</p>
<p>
 157. Whittington WL, Celum CL, Cent A, et al. Use of a glycoprotein G-based type-specific assay to detect antibodies to herpes simplex virus type 2 among persons attending sexually transmitted disease clinics. Sex Transm Dis 2001;28:99&ndash;104.
</p>
<p>
 158. Zimet GD, Rosenthal SL, Fortenberry JD, et al. Factors predicting the acceptance of herpes simplex virus type 2 antibody testing among adolescents and young adults. Sex Transm Dis 2004;31:665&ndash;69.
</p>
<p>
 159. Morrow R, Friedrich D. Performance of a novel test for IgM and IgG antibodies in subjects with culture-documented genital herpes simplex virus-1 or -2 infection. Clin Microbiol Infect 2006;12:463&ndash;9.
</p>
<p>
 160. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 2002;34:958&ndash;62.
</p>
<p>
 161. Wald A, Carrell D, Remington M, et al. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002;34:944&ndash;8.
</p>
<p>
 162. Aoki FY, Tyring S, az-Mitoma F, et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2006;42:8&ndash;13.
</p>
<p>
 163. Chosidow O, Drouault Y, Leconte-Veyriac F, et al. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br J Dermatol 2001;144:818&ndash;24.
</p>
<p>
 164. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Genitourin Med 1997;73:110&ndash;6.
</p>
<p>
 165. Fife KH, Barbarash RA, Rudolph T, et al. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Sex Transm Dis 1997;24:481&ndash;6.
</p>
<p>
 166. Diaz-Mitoma F, Sibbald RG, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. JAMA 1998;280:887&ndash;92.
</p>
<p>
 167. Mertz GJ, Loveless MO, Levin MJ, et al; Collaborative Famciclovir Genital Herpes Research Group. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: a multicenter,&nbsp;double-blind, placebo-controlled trial. Arch Intern Med 1997;157:343&ndash;49.
</p>
<p>
 168. Reitano M, Tyring S, Lang W, et al; International Valaciclovir HSV Study Group. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998;178:603&ndash;10.
</p>
<p>
 169. Romanowski B, Marina RB, Roberts JN. Patients&lsquo; preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex Transm Dis 2003;30:226&ndash;231.
</p>
<p>
 170. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11&ndash;20.
</p>
<p>
 171. Goldberg LH, Kaufman R, Kurtz TO, et al; Acyclovir Study Group. Long-term suppression of recurrent genital herpes with acyclovir: a 5-year benchmark. Arch Dermatol 1993;129:582&ndash;7.
</p>
<p>
 172. Fife KH, Crumpacker CS, Mertz GJ, et al; Acyclovir Study Group. Recurrence and resistance patterns of herpes simplex virus following cessation of &ge;6 years of chronic suppression with acyclovir. J Infect Dis 1994;169:1338&ndash;41.
</p>
<p>
 173. Wald A, Selke S, Warren T, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis 2006;33:529&ndash;33.
</p>
<p>
 174. Gilbert LK, Wyand F. Genital herpes education and counseling: testing a one-page&sbquo; FAQ intervention. Herpes 2009;15:51&ndash;6.
</p>
<p>
 175. Rosenthal SL, Zimet GD, Leichliter JS, et al. The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection. Sex Transm Infect 2006;82:154&ndash;7.
</p>
<p>
 176. Miyai T, Turner KR, Kent CK, et al. The psychosocial impact of testing individuals with no history of genital herpes for herpes simplex virus type 2. Sex Transm Dis 2004;31:517&ndash;21.
</p>
<p>
 177. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008;358:1560&ndash;71.
</p>
<p>
 178. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition&nbsp;in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371(9630):2109&ndash;19.
</p>
<p>
 179. Henry RE, Wegmann JA, Hartle JE, et al. Successful oral acyclovir desensitization. Ann Allergy 1993;70:386&ndash;8.
</p>
<p>
 180. Posavad CM, Wald A, Kuntz S, et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004;190:693&ndash;6.
</p>
<p>
 181. Conant MA, Schacker TW, Murphy RL, et al. Valaciclovir versus aciclovir&nbsp;for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002;13:12&ndash;21.
</p>
<p>
 182. Romanowski B, Aoki FY, Martel AY, et al. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group. AIDS 2000;14:1211&ndash;7.
</p>
<p>
 183. DeJesus E, Wald A, Warren T, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003;188:1009&ndash;16.
</p>
<p>
 184. Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes&nbsp;among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003;163:76&ndash;80.
</p>
<p>
 185. Erard V, Wald A, Corey L, et al. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex&nbsp;virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007;196:266&ndash;70.
</p>
<p>
 186. Brown ZA, Selke S, Zeh, et al. Acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997;337:509&ndash;15.
</p>
<p>
 187. Brown ZA, Wald A, Morrow RA, et al. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003;289:203&ndash;9.
</p>
<p>
 188. Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984&ndash;1999. Birth Defects Res A Clin Mol Teratol 2004;70:201&ndash;7
</p>
<p>
 189. Sheffield JS, Hollier LM, Hill JB, et al. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet Gynecol 2003;102:1396&ndash;1403.
</p>
<p>
 190. Watts DH, Brown ZA, Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol 2003;188:836&ndash;43.
</p>
<p>
 191. Scott LL, Hollier LM, McIntire D, et al. Acyclovir suppression to prevent recurrent genital herpes at delivery. Infect Dis Obstet Gynecol 2002;10:71&ndash;7.
</p>
<p>
 192. O&lsquo;Farrell N. Donovanosis. Sex Transm Infect 2002;78:452&ndash;7.
</p>
<p>
 193. Bowden FJ. Donovanosis in Australia: going, going. Sex Transm Infect 2005;81:365&ndash;6.
</p>
<p>
 194. Mabey D, Peeling RW. Lymphogranuloma venereum. Sex Transm Infect 2002;78:90&ndash;2.
</p>
<p>
 195. Nieuwenhuis RF, Ossewaarde JM, Gotz HM, et al. Resurgence of lymphogranuloma venereum in Western Europe: an outbreak of Chlamydia trachomatis serovar l2 proctitis in the Netherlands among men who have sex with men. Clin Infect Dis 2004;39:996&ndash;1003.
</p>
<p>
 196. Ward H, Martin I, Macdonald N, et al. Lymphogranuloma venereum in the United Kingdom. Clin Infect Dis 2007;44:26&ndash;32.
</p>
<p>
 197. CDC. Guidelines for the laboratory diagnosis of gonorrhea, chlamydia and syphilis. Available at
 <a href="http://www.aphl.org/aphlprograms/infectious/std/Pages/stdtestingguidelines.aspx" rel="external" target="_blank">
  http://www.aphl.org/aphlprograms/infectious/std/Pages/stdtestingguidelines.aspx
 </a>
 .
</p>
<p>
 198. Nandwani R, Evans DT. Are you sure it&rsquo;s syphilis? A review of false positive serology. Int J STD AIDS 1995;6:241&ndash;8.
</p>
<p>
 199. Association of Public Health Laboratories (APHL). Laboratory Diagnostic Testing for Treponema pallidum. Expert Consultation Meeting Summary Report, January 13&ndash;15, 2009, Atlanta, GA. Available at
 <a href="http://www.aphl.org/aphlprograms/infectious/std/Documents/LaboratoryGuidelinesTreponemapallidumMeetingReport.pdf" rel="external" target="_blank">
  http://www.aphl.org/aphlprograms/infectious/std/Documents/LaboratoryGuidelinesTreponemapallidumMeetingReport.pdf
 </a>
 .
</p>
<p>
 200. Romanowski B, Sutherland R, Fick GH, et al. Serologic response to treatment of infectious syphilis. Ann Intern Med 1991;114:1005&ndash;9.
</p>

            </div>
            <script type="text/javascript">

                $('div').live('pageshow', function (event, ui) {
                    document.addEventListener("deviceready", function(){
                        trackReferencesPageView("4");
                                                },true);
                });
            </script>
        </div>
        <!-- end of references heading page -->
    </body>
</html>

    